S415
Clinical - Gynaecological
ESTRO 2026
outcomes in locally advanced cervical cancer: Mature realworld data from LMIC. Sushma Agrawal 1 , Treshita Dey 2 , Senthil SK Kumar 1 1 Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. 2 Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lusknow, India Purpose/Objective: Majority of cervical cancer present as locally advanced disease (LACC) in LMIC. The standard treatment for this is radical chem- oradiotherapy (CTRT) which yields 5-year overall survival (OS) rate between 50%-60%. Long waiting list for initiation of radiotherapy necessitates few cycles neoadjuvant chemotherapy (NACT) prior to CTRT. We present our mature 10-year results of NACT followed by CTRT. Material/Methods: Consecutive patients of de-novo stage 2 and 3 (2014-2023) were initiated on at least 2-3 cycles of NACT (carboplatin 5 AUC and paclitaxel 175mg/m2, 3 weekly). Thereafter patients were treated with concurrent chemoradiation 50Gy/25fractions/5wks by 3D-CRT followed by 3 fractions of brachytherapy (7 Gy prescribed to point A). After completion of treatment, patients were followed up in OPD 3 monthly for two years and thereafter 6 monthly. For the purpose of this analysis patients were also contacted telephonically to know their updated status. Results: Out of 137 patients (median age 55 yrs,50% stage 2 and 3 respectively, 96% squamous histology), 46% received 2 cycles and 54% received 3 cycles NACT. NACT was well tolerated (grade 2 anaemia 12%, grade 2neutropenia 12%, grade 2 thrombocytopenia 5%, grade 2 diarrhoea 7%, grade 2 neuropathy 3%). Thereafter all patients completed radical CTRT. The median number of concurrent cisplatin cycles was 5 (IQR 2-5). CTRT was well tolerated (grade 2 anaemia 6%, grade 2 neutropenia 6%, grade 2 urinary symptoms 10%, grade 2 diarrhoea
Conclusion: OCBM often involves multiple, symptomatic lesions in heavily pre-treated patients. Good ECOG, controlled extra-cranial disease and platinum-sensitive BM predict better survival, supporting personalized RT approach. References: 1. Borella F, Bertero L, Morrone A, Gambella A, Bovetti M, Cosma S, Carosso A, Katsaros D, Gemmiti S, Preti M, et al. Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. Cancers. 2020;12(8):2156. https://doi.org/10.3390/canc ers12082156
Keywords: Ovarian Cancer, Brain Metastases, Platinum resistant
Digital Poster 1070
Neoadjuvant chemotherapy followed by radical chemoradiotherapy improves
Made with FlippingBook - Share PDF online